AG真人官方

LifeVantage Corporation describes its direct-selling dietary supplement and personal-care business, emphasizing a nutrigenomics "activating wellness" strategy and product portfolio including Protandim4, TrueScience4 skin and hair care, AXIO4 energy drinks, Petandim4, and the patent-pending MindBody GLP-1 System42; MB Core42; MB Enhance42. The company reported approximately $220.0 million aggregate market value of common stock held by non-affiliates as of December 31, 2024 and 12,691,009 shares outstanding as of September 3, 2025. As of June 30, 2025 it employed 238 people and had ~51,000 active independent consultants (vs 49,000 in fiscal 2024). Approximately 22% of fiscal 2025 revenue was international, primarily Japan. There was no outstanding balance on the 2024 Credit Facility as of June 30, 2025; the facility matures April 12, 2027. The filing lists material risks including dependence on independent consultants, concentration on a few products, third-party manufacturing and supply-chain risks, regulatory and advertising scrutiny, cybersecurity and data-privacy obligations, potential tax or employment classification exposure for consultants, activist stockholder actions, and foreign currency and market-entry risks.

The Form 4 filed for LifeVantage Corp (LFVN) reports insider activity by CFO Carl Aure. On 08/31/2025 Mr. Aure had 14,792 and 18,886 Performance Restricted Stock Units (PRSUs) marked as acquired (codes M) that convert one-for-one into common stock when vesting criteria are met, and the filing notes those PRSUs were originally granted in 2023 and 2024. The report also reflects 718 shares purchased under the Employee Stock Purchase Plan, and a disposition of 16,610 shares sold at $13.10 per share. Following the transactions, the filing shows total beneficial ownership figures reported per line items.

Kristen Cunningham, Chief Sales Officer of LifeVantage Corp (LFVN), reported changes in her beneficial ownership on a Form 4 covering transactions dated 08/31/2025. The filing shows conversion/acquisition of 17,752 and 26,150 performance restricted stock units (PRSUs) into common stock at no cash price, an ESPP purchase of 254 shares, and a sale of 21,801 common shares at $13.10 per share. After the transactions, reported beneficial ownership totals shown range between 134,357 and 160,507 shares depending on which line is referenced; derivative holdings converted on a one-for-one basis into common stock.

Steven R. Fife, President and CEO and director of Lifevantage Corp (LFVN), reported insider transactions on 08/31/2025. Two tranches of previously granted performance restricted stock units converted into common stock: 90,718 shares (granted 08/24/2023) and 108,960 shares (granted 08/26/2024). Those PRSUs convert one-for-one into common shares and were reported as acquired at $0 under Rule 16 reporting codes. Separately, 98,177 shares were disposed of at a reported price of $13.10, leaving the reporting person with 761,001 and 859,178 total shares following the respective transactions as shown on the form.

Lifevantage Corp (LFVN) reporting person Alissa Neufeld recorded equity activity consisting of performance restricted stock units (PRSUs) and a disposition of common stock. The filing shows PRSUs granted in 2023 and 2024 that convert one-for-one into common stock, two grant-related transactions adding 14,498 and 18,886 shares (Transaction Code M) at $0 per share, and a sale (Transaction Code F) of 15,729 shares at $13.10 per share. After these transactions the reporting person beneficially owned 118,260 common shares.

The derivative section shows the PRSUs underlying 14,498 and 18,886 units, with post-transaction derivative beneficial ownership reported as 4,832 and 9,443 respectively. The filing states the PRSUs vest upon meeting pre-established time-based and financial performance criteria and convert into common stock on a one-for-one basis.

Julie Boyster, identified as an Officer (Chief Marketing Officer), reported Section 16 transactions in Lifevantage Corp (LFVN) on 08/31/2025. Two grants of Performance Restricted Stock Units (PRSUs) converted or vested resulting in acquisitions: 18,934 shares (from a PRSU grant on 08/24/2023) and 27,966 shares (from a PRSU grant on 08/26/2024). The filing states PRSUs convert into common stock on a one-for-one basis. The holder also reported a disposition of 23,293 shares at a price of $13.10 each. Following the reported transactions, the form shows the reporting person beneficially owned 151,923 shares directly. The form is signed by a power of attorney on behalf of Julie Boyster.

Alissa Neufeld, General Counsel of Lifevantage Corp (LFVN), received equity awards on 08/26/2025. The Form 4 shows an award of 9,036 stock units and 13,554 Performance Restricted Stock Units (PRSUs). After the grant, Ms. Neufeld beneficially owns 100,605 shares of common stock and 13,554 PRSU equivalents. The stock units vest with 5/12 of the award on September 10, 2026 and the remainder in equal installments on the tenth day of the third month of each of seven subsequent calendar quarters. The PRSUs vest only if performance targets are met (target payout shown); upon maximum performance the award may pay up to 200% of target, with vested portions scheduled 34% on Sept 10, 2026, 33% on Sept 10, 2027, and 33% on Sept 10, 2028.

Lifevantage Corp (LFVN) reported a Form 4 showing equity awards to Julie Boyster, the company's Chief Marketing Officer. The filing discloses a non鈥慸erivative grant of 13,102 common stock units on 08/26/2025, increasing her directly held common shares to 128,316. The filing also shows 19,654 Performance Restricted Stock Units (PRSUs) granted the same date, representing rights to receive that many shares if performance targets are met; the PRSUs count as 19,654 underlying shares for beneficial ownership. The stock units vest over time subject to continued service: 5/12 of the stock unit award vests on September 10, 2026, with the remainder in equal installments across seven calendar quarters thereafter. The PRSUs vest only to the extent financial performance criteria are achieved and, if earned, vest in three tranches on September 10, 2026, 2027 and 2028 (34%, 33%, 33%). The Form 4 was signed by a power of attorney on 08/28/2025.

Lifevantage Corp (LFVN) reporting person Steven R. Fife, President and CEO and a director, received non鈥慸erivative and derivative equity awards on 08/26/2025. He was granted 48,193 stock units that represent rights to receive common stock and will hold 659,500 shares beneficially following the grant. He also received 72,289 Performance Restricted Stock Units (PRSUs) at target, with each PRSU representing one share at $0 exercise price; PRSU vesting is contingent on performance and continued service.

The stock units vest partly on September 10, 2026 and then in installments across seven quarters; PRSU vesting, if earned, vests 34% on September 10, 2026, 33% on September 10, 2027 and 33% on September 10, 2028. The Form 4 was signed by a power of attorney on 08/28/2025.